Treatment of Metastatic Triple-Negative Breast Cancer
Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).
Most trials reported today are in metastatic TNBC, but areas that need more attention are HER2+ disease and hormone-refractory hormone-receptor positive breast cancer, said Nanda. Knowledge of the role of immune checkpoint inhibition within these subtypes of breast cancer is needed as well.
Nanda is also hoping combination therapy with immune checkpoint inhibitors, vaccines, and other therapies will help to improve the current response rates.
Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
